Private Bank & Trust Co. reduced its position in Sanofi (NYSE:SNY) by 4.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,868 shares of the company’s stock after selling 247 shares during the period. Private Bank & Trust Co.’s holdings in Sanofi were worth $281,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the company. Fisher Asset Management LLC boosted its position in Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock worth $653,419,000 after buying an additional 1,022,953 shares in the last quarter. Wells Fargo & Company MN boosted its position in Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares during the period. Global Financial Private Capital LLC acquired a new position in Sanofi during the first quarter valued at approximately $35,034,000. Karp Capital Management Corp acquired a new position in Sanofi during the first quarter valued at approximately $26,174,000. Finally, Bank of America Corp DE boosted its position in Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock valued at $340,792,000 after buying an additional 572,652 shares during the period. Hedge funds and other institutional investors own 9.97% of the company’s stock.

Shares of Sanofi (NYSE:SNY) traded up 1.53% during midday trading on Tuesday, reaching $48.44. The company’s stock had a trading volume of 408,798 shares. The stock has a 50 day moving average price of $48.25 and a 200-day moving average price of $45.52. The company has a market capitalization of $122.33 billion, a price-to-earnings ratio of 11.68 and a beta of 0.89. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24.

Sanofi (NYSE:SNY) last announced its quarterly earnings results on Friday, April 28th. The company reported $0.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The business had revenue of $8.65 billion for the quarter, compared to analyst estimates of $8.40 billion. Sanofi had a return on equity of 25.89% and a net margin of 26.55%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. Equities research analysts expect that Sanofi will post $3.20 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/07/25/private-bank-trust-co-has-281000-stake-in-sanofi-sny.html.

Several equities analysts have recently commented on SNY shares. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. J P Morgan Chase & Co reiterated a “sell” rating on shares of Sanofi in a research note on Wednesday, April 5th. HSBC Holdings plc cut Sanofi from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. Finally, BidaskClub upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $67.67.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.